These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38626341)

  • 1. De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression.
    Tangudu NK; Buj R; Wang H; Wang J; Cole AR; Uboveja A; Fang R; Amalric A; Yang B; Chatoff A; Crispim CV; Sajjakulnukit P; Lyons MA; Cooper K; Hempel N; Lyssiotis CA; Chandran UR; Snyder NW; Aird KM
    Cancer Res Commun; 2024 May; 4(5):1174-1188. PubMed ID: 38626341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo purine metabolism is a metabolic vulnerability of cancers with low p16 expression.
    Tangudu NK; Buj R; Wang H; Wang J; Cole AR; Uboveja A; Fang R; Amalric A; Sajjakulnukit P; Lyons MA; Cooper K; Hempel N; Snyder NW; Lyssiotis CA; Chandran UR; Aird KM
    bioRxiv; 2023 Sep; ():. PubMed ID: 37503050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
    Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
    Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
    Nielsen GP; Burns KL; Rosenberg AE; Louis DN
    Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming.
    Buj R; Chen CW; Dahl ES; Leon KE; Kuskovsky R; Maglakelidze N; Navaratnarajah M; Zhang G; Doan MT; Jiang H; Zaleski M; Kutzler L; Lacko H; Lu Y; Mills GB; Gowda R; Robertson GP; Warrick JI; Herlyn M; Imamura Y; Kimball SR; DeGraff DJ; Snyder NW; Aird KM
    Cell Rep; 2019 Aug; 28(8):1971-1980.e8. PubMed ID: 31433975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent genetic defects in the p16/INK4A tumor suppressor in canine cell models of breast cancer and melanoma.
    Lutful Kabir FM; DeInnocentes P; Bird AC; Bird RC
    In Vitro Cell Dev Biol Anim; 2021 May; 57(5):519-530. PubMed ID: 34014456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDKN2A/p16 is inactivated in most melanoma cell lines.
    Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
    Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.
    Zeng H; Jorapur A; Shain AH; Lang UE; Torres R; Zhang Y; McNeal AS; Botton T; Lin J; Donne M; Bastian IN; Yu R; North JP; Pincus L; Ruben BS; Joseph NM; Yeh I; Bastian BC; Judson RL
    Cancer Cell; 2018 Jul; 34(1):56-68.e9. PubMed ID: 29990501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy.
    Casula M; Muggiano A; Cossu A; Budroni M; Caracò C; Ascierto PA; Pagani E; Stanganelli I; Canzanella S; Sini M; Palomba G; ; Palmieri G
    BMC Cancer; 2009 Oct; 9():352. PubMed ID: 19799798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of Both CDKN2A and CDKN2B Allows for Centrosome Overduplication in Melanoma.
    Patel S; Wilkinson CJ; Sviderskaya EV
    J Invest Dermatol; 2020 Sep; 140(9):1837-1846.e1. PubMed ID: 32067956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.
    Ming Z; Lim SY; Rizos H
    Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33076392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of CDKN2A (p16INK4A/p14ARF) Over-Expression on Proliferation and Migration of Human Melanoma A375 Cells.
    Bai M; Yu NZ; Long F; Feng C; Wang XJ
    Cell Physiol Biochem; 2016; 40(6):1367-1376. PubMed ID: 27997910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth.
    Williams RT; Barnhill LM; Kuo HH; Lin WD; Batova A; Yu AL; Diccianni MB
    PLoS One; 2014; 9(2):e88219. PubMed ID: 24505435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor suppressor gene p16/INK4A/CDKN2A-dependent regulation into and out of the cell cycle in a spontaneous canine model of breast cancer.
    Agarwal P; Sandey M; DeInnocentes P; Bird RC
    J Cell Biochem; 2013 Jun; 114(6):1355-63. PubMed ID: 23238983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfection of an inducible p16/CDKN2A construct mediates reversible growth inhibition and G1 arrest in the AtT20 pituitary tumor cell line.
    Frost SJ; Simpson DJ; Clayton RN; Farrell WE
    Mol Endocrinol; 1999 Nov; 13(11):1801-10. PubMed ID: 10551774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma.
    Kreuger IZM; Slieker RC; van Groningen T; van Doorn R
    J Invest Dermatol; 2023 Jan; 143(1):18-25.e1. PubMed ID: 36123181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP- malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis.
    Chen ZH; Olopade OI; Savarese TM
    Mol Pharmacol; 1997 Nov; 52(5):903-11. PubMed ID: 9351982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.
    Yang G; Rajadurai A; Tsao H
    J Invest Dermatol; 2005 Dec; 125(6):1242-51. PubMed ID: 16354195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.
    Becker TM; Rizos H; Kefford RF; Mann GJ
    Clin Cancer Res; 2001 Oct; 7(10):3282-8. PubMed ID: 11595726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma.
    Ghiorzo P; Gargiulo S; Pastorino L; Nasti S; Cusano R; Bruno W; Gliori S; Sertoli MR; Burroni A; Savarino V; Gensini F; Sestini R; Queirolo P; Goldstein AM; Scarrà GB
    Hum Mol Genet; 2006 Sep; 15(18):2682-9. PubMed ID: 16893909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.